Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
LAE-005 by Laekna for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
LAE-005 is under clinical development by Laekna and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...
LAE-001 by Laekna for Hormone-Sensitive Prostate Cancer: Likelihood of Approval
LAE-001 is under clinical development by Laekna and currently in Phase II for Hormone-Sensitive Prostate Cancer. According to GlobalData, Phase...
Afuresertib hydrochloride by Laekna for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Afuresertib hydrochloride is under clinical development by Laekna and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...
Afuresertib hydrochloride by Laekna for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Afuresertib hydrochloride is under clinical development by Laekna and currently in Phase III for Human Epidermal Growth Factor Receptor 2...